Orilissa receives FDA approval

The FDA has approved AbbVie’s Orilissa, a treatment for pain associated with endometriosis. This is the first oral drug to receive approval in over a decade. It's expected to roll out in early August with an $845 per month price tag.

AbbVie has already begun grooming the market for Orilissa’s arrival. In an attempt to raise awareness of the disorder, which affects an estimated one in 10 U.S. women of reproductive age, and shorten the timeline to diagnosis, the company has released a doctor’s office TV ad and a campaign featuring Julianne Hough of “Dancing with the Stars.”

Click here to view the entire article.